Edwards Lifesciences Corp: Form 10-K for the period ended Dec 31, 2020
Filed with the SEC on Feb 12, 2021 and accepted by EDGAR at Feb 12, 2021, 16:58 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2020-12-31. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2020-10-01 to 2020-12-31 | $1.19bn | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Revenue | 12 months2020-01-01 to 2020-12-31 | $4.39bn | us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax |
| Cost of revenue | 12 months2020-01-01 to 2020-12-31 | $1.08bn | us-gaap:CostOfGoodsAndServicesSold |
| Gross profit | 3 months2020-10-01 to 2020-12-31 | $895.4m | us-gaap:GrossProfit |
| Gross profit | 12 months2020-01-01 to 2020-12-31 | $3.31bn | us-gaap:GrossProfit |
| Research and development | 12 months2020-01-01 to 2020-12-31 | $760.7m | us-gaap:ResearchAndDevelopmentExpense |
| Selling, general and administrative | 12 months2020-01-01 to 2020-12-31 | $1.23bn | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 12 months2020-01-01 to 2020-12-31 | $897.6m | us-gaap:OperatingIncomeLoss |
| Interest expense | 12 months2020-01-01 to 2020-12-31 | $15.8m | us-gaap:InterestExpense |
| Income tax | 12 months2020-01-01 to 2020-12-31 | $93.3m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2020-10-01 to 2020-12-31 | $309.5m | us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic |
| Net income | 12 months2020-01-01 to 2020-12-31 | $823.4m | us-gaap:NetIncomeLossAvailableToCommonStockholdersBasic |
| Diluted EPS | 3 months2020-10-01 to 2020-12-31 | $0.49 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 12 months2020-01-01 to 2020-12-31 | $1.30 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2020-10-01 to 2020-12-31 | $0.50 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 12 months2020-01-01 to 2020-12-31 | $1.32 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 12 months2020-01-01 to 2020-12-31 | 631,900,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 12 months2020-01-01 to 2020-12-31 | $1.05bn | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 12 months2020-01-01 to 2020-12-31 | $407.0m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Share repurchases | 12 months2020-01-01 to 2020-12-31 | $625.4m | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2020-12-31 | $1.18bn | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2020-12-31 | $3.09bn | us-gaap:AssetsCurrent |
| Total assets | At period end2020-12-31 | $7.24bn | us-gaap:Assets |
| Current liabilities | At period end2020-12-31 | $893.9m | us-gaap:LiabilitiesCurrent |
| Long-term debt | At period end2020-12-31 | $595.0m | us-gaap:LongTermDebtNoncurrent |
| Shareholders' equity | At period end2020-12-31 | $4.57bn | us-gaap:StockholdersEquity |
Source: SEC EDGAR, the filing index for accession 0001099800-21-000007. Last ingested by Listed: Nov 15, 2026, 03:19 ET. Listed shows no prices and gives no investment advice.